Changlei Bao, Shuxin Liang, Ying Han, Zi Yang, Shiyun Liu, Yanan Sun, Shichuang Zheng, Yuzhu Li, Ting Wang, Yali Gu, Kang Wu, Stephen M Black, Jian Wang, Steffan T Nawrocki, Jennifer S Carew, Jason X-J Yuan, Haiyang Tang
BACKGROUND: Autophagy plays an important role in the pathogenesis of pulmonary hypertension (PH). ROC-325 is a novel small molecule lysosomal autophagy inhibitor that has more potent anticancer activity than the antimalarial drug hydroxychloroquine, the latter has been prevalently used to inhibit autophagy. Here, we sought to determine the therapeutic benefit and mechanism of action of ROC-325 in experimental PH models. METHODS AND RESULTS: Hemodynamics, echocardiography, and histology measurement showed that ROC-325 treatment prevented the development of PH, right ventricular hypertrophy, fibrosis, dysfunction, and vascular remodeling after monocrotaline and Sugen5416/hypoxia administration...
November 8, 2022: Hypertension